AGIOS PHARMACEUTICALS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$32.22 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-14.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-02-14
- AGIOS PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$85.98M.
- AGIOS PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$53.84M.
- AGIOS PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$154.15M.
- AGIOS PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $261.75M, a 562.24% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$32.22M.
- AGIOS PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$58.03M, a 165.21% decline from fiscal 2016.
- AGIOS PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $88.99M, a 54.14% increase from fiscal 2015.
- AGIOS PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $57.73M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$85.98M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | -$139.82M derived: sum of 2 quarters · filed 2019-02-14 | -$293.97M derived: sum of 3 quarters · filed 2019-02-14 | -$32.22M 10-K · filed 2019-02-14 |
| 2018-09-30 | -$53.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$207.99M derived: sum of 2 quarters · filed 2018-11-01 | $53.75M 10-Q · filed 2018-11-01 | $23.74M derived: sum of 4 quarters · filed 2019-02-14 |
| 2018-06-30 | -$154.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $107.60M 10-Q · filed 2018-08-02 | $77.58M derived: sum of 3 quarters · filed 2019-02-14 | $71.61M derived: sum of 4 quarters · filed 2019-02-14 |
| 2018-03-31 | $261.75M 10-Q · filed 2018-05-04 | $231.73M derived: sum of 2 quarters · filed 2019-02-14 | $225.75M derived: sum of 3 quarters · filed 2019-02-14 | $164.19M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-12-31 | -$30.02M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | -$35.99M derived: sum of 2 quarters · filed 2019-02-14 | -$97.55M derived: sum of 3 quarters · filed 2019-02-14 | -$58.03M 10-K · filed 2019-02-14 |
| 2017-09-30 | -$5.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$67.54M derived: sum of 2 quarters · filed 2018-11-01 | -$28.01M 10-Q · filed 2018-11-01 | -$152.76M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-06-30 | -$61.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$22.04M 10-Q · filed 2018-08-02 | -$146.78M derived: sum of 3 quarters · filed 2019-02-14 | -$95.33M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-03-31 | $39.52M 10-Q · filed 2018-05-04 | -$85.22M derived: sum of 2 quarters · filed 2019-02-14 | -$33.77M derived: sum of 3 quarters · filed 2019-02-14 | $161.24M derived: sum of 4 quarters · filed 2019-02-14 |
| 2016-12-31 | -$124.75M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | -$73.29M derived: sum of 2 quarters · filed 2019-02-14 | $121.72M derived: sum of 3 quarters · filed 2019-02-14 | $88.99M 10-K · filed 2019-02-14 |
| 2016-09-30 | $51.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $246.47M derived: sum of 2 quarters · filed 2017-11-01 | $213.74M 10-Q · filed 2017-11-01 | $205.45M derived: sum of 4 quarters · filed 2018-02-14 |
| 2016-06-30 | $195.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $162.28M 10-Q · filed 2017-08-08 | $154.00M derived: sum of 3 quarters · filed 2018-02-14 | $161.51M derived: sum of 4 quarters · filed 2018-02-14 |
| 2016-03-31 | -$32.73M 10-Q · filed 2017-05-04 | -$41.01M derived: sum of 2 quarters · filed 2018-02-14 | -$33.50M derived: sum of 3 quarters · filed 2018-02-14 | $3.78M derived: sum of 4 quarters · filed 2018-02-14 |
| 2015-12-31 | -$8.28M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | -$769.00K derived: sum of 2 quarters · filed 2018-02-14 | $36.51M derived: sum of 3 quarters · filed 2018-02-14 | $57.73M 10-K · filed 2018-02-14 |
| 2015-09-30 | $7.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $44.79M derived: sum of 2 quarters · filed 2016-11-03 | $66.02M 10-Q · filed 2016-11-03 | $10.00M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-06-30 | $37.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $58.50M 10-Q · filed 2016-08-08 | $2.48M derived: sum of 3 quarters · filed 2017-02-16 | -$35.71M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-03-31 | $21.23M 10-Q · filed 2016-05-09 | -$34.79M derived: sum of 2 quarters · filed 2017-02-16 | -$72.99M derived: sum of 3 quarters · filed 2017-02-16 | $2.42M derived: sum of 4 quarters · filed 2017-02-16 |
| 2014-12-31 | -$56.02M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | -$94.22M derived: sum of 2 quarters · filed 2017-02-16 | -$18.81M derived: sum of 3 quarters · filed 2017-02-16 | -$57.53M 10-K · filed 2017-02-16 |
| 2014-09-30 | -$38.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $37.21M derived: sum of 2 quarters · filed 2015-11-06 | -$1.51M 10-Q · filed 2015-11-06 | -$35.96M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | $75.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $36.69M 10-Q · filed 2015-08-07 | $2.24M derived: sum of 3 quarters · filed 2016-02-26 | $30.77M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | -$38.72M 10-Q · filed 2015-05-11 | -$73.17M derived: sum of 2 quarters · filed 2016-02-26 | -$44.64M derived: sum of 3 quarters · filed 2016-02-26 | -$50.54M derived: sum of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | -$34.45M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | -$5.92M derived: sum of 2 quarters · filed 2016-02-26 | -$11.82M derived: sum of 3 quarters · filed 2016-02-26 | -$19.74M 10-K · filed 2016-02-26 |
| 2013-09-30 | $28.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $22.63M derived: sum of 2 quarters · filed 2014-11-07 | $14.71M 10-Q · filed 2014-11-07 | $22.98M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | -$5.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$13.82M 10-Q · filed 2014-08-07 | -$5.55M derived: sum of 3 quarters · filed 2015-02-24 | -$18.64M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | -$7.92M 10-Q · filed 2014-05-09 | $342.00K derived: sum of 2 quarters · filed 2015-02-24 | -$12.74M derived: sum of 3 quarters · filed 2015-02-24 | |
| 2012-12-31 | $8.26M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | -$4.83M derived: sum of 2 quarters · filed 2015-02-24 | -$26.36M 10-K · filed 2015-02-24 | |
| 2012-09-30 | -$13.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$34.63M 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | -$21.54M 10-Q · filed 2013-09-05 | |||
| 2011-12-31 | $39.78M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |